E-resources
Peer reviewed
Open access
-
PUOTI, Massimo; COZZI-LEPRI, Alessandro; D'ARMINIO MONFORTE, Antonnella; ANCARANI, Fausto; BRUNO, Raffaele; AMBU, Silvia; FERRARO, Teresa; TUNDO, Paolo; SANTANTONIO, Teresa; TOTI, Mario; BONASSO, Marino
Antiviral therapy 9, Issue: 5Journal Article
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up -81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003 and a significantly reduced risk of liver-related morbidity/mortality Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002 than those starting a lamivudine sparing-regimen.
